SCHEMBL89072

SCHEMBL89072

COc1cccc(C)c1NC(=O)[C@H]1C[C@@H](C(=O)O)CN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.42
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
PDE4B Q07343 3/20 0.40
PTPN2 P17706 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN6 P29350 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
EHMT2 Q96KQ7 1/20 0.39
STS P08842 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
ABL1 P00519 1/20 0.38
RIN1 Q13671 1/20 0.38
SCN4A P35499 2/20 0.38
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
APLNR P35414 1/20 0.38
REN P00797 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL89832 0.92 PDE4B (0.45) NPSR1GAAMAPTPDE4BPTPN2
SCHEMBL8235795 0.79 MAPT (0.47) NPSR1MAPTPTPN2PTPN1PTPN6
SCHEMBL1911378 0.76 REN (0.44) NPSR1GAAMAPTPDE4BMEN1
SCHEMBL27042699 0.74 SMN1; SMN2 (0.50) GAAMAPTPDE4BPTPN2PTPN1
SCHEMBL57263 0.73 NR1H2 (0.54) MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL89062 0.73 NR1H2 (0.54) MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL20220628 0.73 NR1H2 (0.54) MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL90006 0.73 RORC (0.44) PTPN2PTPN1PTPN6STSABL1
SCHEMBL14089226 0.73 NR1H2 (0.46) MAPTPDE4BPTPN2PTPN1PTPN6
SCHEMBL89862 0.72 RECQL (0.53) MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129411-B2 Organic compounds NOVARTIS AG (CH) 2012-03-06 US disclosed
EP-2420491-A1 3 , 5-substitued piperidine compounds as renin inhibitors Novartis AG (CH) 2012-02-22 EP disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
US-20090192148-A1 Organic Compounds NOVARTIS AG (CH) 2009-07-30 US disclosed
WO-2007077005-A1 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS NOVARTIS AG (CH) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192148-A1 Organic Compounds REN, ACE, AGTR1 NPSR1 942/4885GAA 309/4885MAPT 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.